Alpha 2.0
Login Register
» Articles » PMID: 39144788

Placebos in Schizophrenia Research: An Historical Overview and Introduction to Ethical Issues

Overview
Journal Schizophr Bull Open
Date 2024 Aug 15
PMID 39144788
Authors
Suze G Berkhout
Affiliations
Soon will be listed here.
Abstract

This short introduction provides a historical and ethical overview of placebos and placebo controls in relation to schizophrenia research, with a focus on long-term clinical trials. Drawing on historical and philosophical scholarship, it sketches a two-level analysis of ethical issues that placebos and the placebo effect raise for the field, particularly in light of shifts in clinical trial methodologies and clinical practices.

References
1.
Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M . Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005; 187:229-34. DOI: 10.1192/bjp.187.3.229. View
2.
Viswanathan M, Ammerman A, Eng E, Garlehner G, Lohr K, Griffith D . Community-based participatory research: assessing the evidence. Evid Rep Technol Assess (Summ). 2004; (99):1-8. PMC: 4780908. View
3.
Fava M, Evins A, Dorer D, Schoenfeld D . The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003; 72(3):115-27. DOI: 10.1159/000069738. View
4.
Gifford F . Pulling the plug on clinical equipoise: a critique of Miller and Weijer. Kennedy Inst Ethics J. 2008; 17(3):203-26. DOI: 10.1353/ken.2007.0020. View
5.
Flacco M, Manzoli L, Boccia S, Capasso L, Aleksovska K, Rosso A . Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol. 2015; 68(7):811-20. DOI: 10.1016/j.jclinepi.2014.12.016. View